TGFB1 and neoplasm: Next, to test whether the normalization of tumor blood vessels and ECM can improve intratumoral nanomedicine delivery, we treated tumor‐bearing mice with combined DC101 and anti‐TGFβ1 antibody and measured the distribution of nanoparticles within the tumor interstitium.